secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-06-17T20:50:41+00:00
Accession:  0001104659-26-075198
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio stockholders elect all five director nominees and approve all proposals at 2026 annual meeting
--------------------------------------------------------------------------------

- All five director nominees elected; broker non-vote 12.55M shares abstained.
- Ratification of Ernst & Young as auditors passed: 20.63M for, 568k against.
- Equity plan amendment approved: share pool increased from 4M to 5.5M.
- Say-on-pay advisory vote approved: 8.07M for, 901k against.
- Advisory vote on frequency: 'Two Years' selected; Company will hold every two years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/0001104659-26-075198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/tm2617993d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-075198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer